刚谈完就扯皮！美欧对关税协议细节“各执一词”

Group 1 - The core issue in the US-EU trade negotiations is significant disagreement over pharmaceutical tariffs, which has become a major obstacle [1] - The new trade agreement includes a 15% tariff on EU products entering the US and a commitment from the EU to invest an additional $600 billion and purchase $750 billion worth of US energy [1] - There is a preliminary consensus on the 15% tariff for EU pharmaceutical exports, but the US plans to initiate a Section 232 investigation into the pharmaceutical sector in the coming weeks [1][3] Group 2 - The agreement framework lacks specific details, making it appear overly simplistic compared to typical trade agreements that require years of negotiation and extensive documentation [2] - The focus will now shift to the risks associated with the interpretation and implementation of the agreement, which involves a mix of political and technical issues [3] - The US has begun investigations to assess whether imports in sectors like aerospace and semiconductors pose a national security threat, which could lead to additional tariffs [3]